Risks and Benefits of Glucocorticoids in ANCA-Associated Vasculitis

Wilde B, van Paassen P, Witzke O, Tervaert JW. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int. 2011;79(6):599–612. https://doi.org/10.1038/ki.2010.472. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev. Rheumatol. 2014;10(8):463–73. https://doi.org/10.1038/nrrheum.2014.103. Kemna MJ, Plomp R, van Paassen P, Koeleman CA, Jansen BC, Damoiseaux JG, et al. Galactosylation and sialylation levels of IgG predict relapse in patients with PR3-ANCA associated vasculitis. EBioMedicine. 2017;17:108–18. https://doi.org/10.1016/j.ebiom.2017.01.033. Rimbert M, Hamidou M, Braudeau C, Puechal X, Teixeira L, Caillon H, et al. Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One. 2011;6(4):e18734. https://doi.org/10.1371/journal.pone.0018734. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955–63. https://doi.org/10.1172/JCI15918. Charles Jennette J, Xiao H, Hu P. Complement in ANCA-associated vasculitis. Semin Nephrol. 2013;33(6):557–64. https://doi.org/10.1016/j.semnephrol.2013.08.006. Manenti L, Urban ML, Maritati F, Galetti M, Vaglio A. Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. Intern Emerg Med. 2017; https://doi.org/10.1007/s11739-017-1636-6. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55(7):603–13. Barnes PJ, Adcock IM. NF-kappa B: a pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci. 1997;18(2):46–50. Rota S, Rambaldi A, Gaspari F, Noris M, Daina E, Benigni A, et al. Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney Int. 1992;42(4):981–90. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–26. https://doi.org/10.1002/acr.20295. Palmowski Y, Buttgereit T, Dejaco C, Bijlsma JW, Matteson EL, Voshaar M, et al. The “official view” on glucocorticoids in rheumatoid arthritis. A systematic review of international guidelines and consensus statements. Arthritis Care Res (Hoboken). 2016; https://doi.org/10.1002/acr.23185. •• Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis & Rheumatology. 2017;69(8):1521–37. https://doi.org/10.1002/art.40137. This is the most recent guidance on preventing one of the most common side-effects of glucocortoids, osteoporosis. These guidelines deviate from prior guidelines somewhat in their integration of risk factors beyond glucocorticoid dose. Slot MC, Tervaert JW, Franssen CF, Stegeman CA. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int. 2003;63(2):670–7. https://doi.org/10.1046/j.1523-1755.2003.00769.x. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248(4):564–77. https://doi.org/10.1097/SLA.0b013e318187d1da. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation. 2010;89(1):1–14. https://doi.org/10.1097/TP.0b013e3181c518cc. Hricik DE, O’Toole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol. 1993;4(6):1300–5. Rizzari MD, Suszynski TM, Gillingham KJ, Dunn TB, Ibrahim HN, Payne WD, et al. Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol. 2012;7(3):494–503. https://doi.org/10.2215/CJN.08630811. •• Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662–1668.This randomized controlled trial suggests that continuation of both low-dose glucocorticoids and azathioprine significantly reduces the risk of relapse in patients with ANCA-associated vasculitis. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med. 1995;333(3):142–6. https://doi.org/10.1056/NEJM199507203330302. Treatment of polyarteritis nodosa with cortisone: results after three years: Report to the Medical Research Council by the Collagen Diseases and Hypersensitivity Panel. Br Med J. 1960;1(5183):1399–400. Ntatsaki E, Carruthers D, Chakravarty K, D’Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology. 2014;53(12):2306–9. https://doi.org/10.1093/rheumatology/ket445. McGeoch L, Twilt M, Famorca L, Bakowsky V, Barra L, Benseler SM, et al. CanVasc Recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. The Journal of Rheumatology. 2016;43(1):97–120. https://doi.org/10.3899/jrheum.150376. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310–7. https://doi.org/10.1136/ard.2008.088096. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Annals of Internal Medicine. 2009;150(10):670–80. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20. https://doi.org/10.1056/NEJMoa0909169. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32. https://doi.org/10.1056/NEJMoa0909905. Famorca L, Twilt M, Barra L, Bakowsky V, Benseler S, Cabral D, et al. Development of Canadian recommendations for the management of ANCA-associated vasculitides: results of the National Needs Assessment Questionnaire. The Open Rheumatology Journal. 2015;9:16–20. https://doi.org/10.2174/18743129014090100016. Rodrigues JC, Collister D, Archer A, Cheema K, Alexander P, Pagnoux C, et al. The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: a systematic review and meta-analysis. Rheumatology. 2017;56(suppl_3):iii103. https://doi.org/10.1093/rheumatology/kex110. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res. 2010;62(8):1166–73. Pagnoux C, Quemeneur T, Ninet J, Diot E, Kyndt X, de Wazieres B, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis & Rheumatology. 2015;67(4):1117–27. https://doi.org/10.1002/art.39011. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180–8. https://doi.org/10.1681/ASN.2007010090. Walsh M, Casian A, Flossmann O, Westman K, Hoglund P, Pusey C, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397–402. https://doi.org/10.1038/ki.2013.131. Walsh M, Merkel PA, Peh CA, Szpirt W, Guillevin L, Pusey CD, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:73. https://doi.org/10.1186/1745–6215–14-73. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–65. https://doi.org/10.1136/hrt.2003.020180. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Annals of Internal Medicine. 2004;141(10):764–70. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Gonzalez-Gay MA. Steroid therapy improves endothelial function in patients with biopsy-proven giant cell arteritis. The Journal of Rheumatology. 2006;33(1):74–8. Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(9):842–5. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488–94. https://doi.org/10.1136/ard.2010.137778. Suppiah R, Judge A, Batra R, Flossmann O, Harper L, Hoglund P, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63(4):588–96. https://doi.org/10.1002/acr.20433. Pagnoux C, Chironi G, Simon A, Guillevin L. Atherosclerosis in ANCA-associated vasculitides. Annals of the New York Academy of Sciences. 2007;1107:11–21. https://doi.org/10.1196/annals.1381.002. Booth AD, Wallace S, McEniery CM, Yasmin, Brown J, Jayne DR, et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum. 2004;50(2):581–8. https://doi.org/10.1002/art.20002. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007;2(6):1241–8. https://doi.org/10.2215/CJN.02190507. Les I, Pijoan JI, Rodriguez-Alvarez R, Ruiz-Irastorza G, Martinez-Berriotxoa A. Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-90-7. Singh RG, Kassir M, Roistacher N, Lerman BB, Kligfield P. Acceleration of atrioventricular conduction during corticosteroid therapy. Am Heart J. 1993;125(5 Pt 1):1432–4. van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016–20. https://doi.org/10.1001/archinte.166.9.1016. Nikkel LE, Mohan S, Zhang A, McMahon DJ, Boutroy S, Dube G, et al. Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012;12(3):649–59. https://doi.org/10.1111/j.1600-6143.2011.03872.x. Lems WF, Baak MM, van Tuyl LH, Lodder MC, Dijkmans BA, Boers M. One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy. RMD Open. 2016;2(2):e000313. https://doi.org/10.1136/rmdopen-2016-000313. Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O’Malley CD, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016;27(11):3239–49. https://doi.org/10.1007/s00198-016-3646-z. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. The American Journal of Medicine. 1994;96(2):115–23. Boomsma MM, Stegeman CA, Kramer AB, Karsijns M, Piers DA, Tervaert JW. Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos Int. 2002;13(1):74–82. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628–34. https://doi.org/10.1002/art.21568. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7(2):240–7. https://doi.org/10.2215/CJN.05610611. Pirsch JD, Henning AK, First MR, Fitzsimmons W, Gaber AO, Reisfield R, et al. New-onset diabetes after transplantation: results from a double-blind early corticosteroid withdrawal trial. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2015;15(7):1982–90. https://doi.org/10.1111/ajt.13247. Movahedi M, Beauchamp ME, Abrahamowicz M, Ray DW, Michaud K, Pedro S, et al. Risk of incident diabetes mellitus associated with the dosage and duration of oral glucocorticoid therapy in patients with rheumatoid arthritis. Arthritis. Rheumatology. 2016;68(5):1089–98. https://doi.org/10.1002/art.39537. Robson J, Ashdown S, Dawson J, Easley E, Gebhart D, Kellom K et al. Patient perceptions of treatment with glucocorticoids in ANCA-associated vasculitis. Arthritis Rheumatology. 2015;67(Supplement 10):1165-1166.